Sarepta Therapeutics (SRPT) Total Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Total Liabilities fell 27.93% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (down 27.93% YoY), while the FY2025 annual figure was $2.2 billion, down 9.29% from the prior year.
• Total Liabilities for Q1 2026 stood at $1.7 billion, down from $2.2 billion in the prior quarter.
• The five-year high for Total Liabilities was $2.7 billion in Q4 2022, with the low at $1.7 billion in Q1 2026.
• The 5-year median for Total Liabilities is $2.3 billion (2023), against an average of $2.3 billion.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities climbed 24.29% in 2022, then declined 27.93% in 2026.
• Sarepta Therapeutics' Total Liabilities stood at $2.7 billion in 2022, then slipped by 12.33% to $2.4 billion in 2023, then gained by 1.26% to $2.4 billion in 2024, then fell by 9.29% to $2.2 billion in 2025, then dropped by 24.23% to $1.7 billion in 2026.
• Business Quant data shows SRPT's Total Liabilities at $1.7 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.2 billion in Q3 2025.